Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
156
archived clinical trials in
ALS

Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Multi-Center Controlled Screening Trial of Safety and Efficacy of Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  12/31/1969
California Pacific Medical Center
mi
from
San Francisco, CA
Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Multi-Center Controlled Screening Trial of Safety and Efficacy of Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 12/31/1969
California Pacific Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Multi-Center Controlled Screening Trial of Safety and Efficacy of Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  12/31/1969
University of Kansas Medical Center
mi
from
Kansas City, KA
Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Multi-Center Controlled Screening Trial of Safety and Efficacy of Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 12/31/1969
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Multi-Center Controlled Screening Trial of Safety and Efficacy of Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  12/31/1969
Phoenix Neurological Institute
mi
from
Phoenix, AZ
Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Multi-Center Controlled Screening Trial of Safety and Efficacy of Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 12/31/1969
Phoenix Neurological Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Multi-Center Controlled Screening Trial of Safety and Efficacy of Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  12/31/1969
University of Iowa
mi
from
Iowa City, IA
Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Multi-Center Controlled Screening Trial of Safety and Efficacy of Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 12/31/1969
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Multi-Center Controlled Screening Trial of Safety and Efficacy of Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  12/31/1969
Univ of Minnesota
mi
from
Minneapolis, MN
Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Multi-Center Controlled Screening Trial of Safety and Efficacy of Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 12/31/1969
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Multi-Center Controlled Screening Trial of Safety and Efficacy of Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  12/31/1969
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Multi-Center Controlled Screening Trial of Safety and Efficacy of Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 12/31/1969
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Multi-Center Controlled Screening Trial of Safety and Efficacy of Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Multi-Center Controlled Screening Trial of Safety and Efficacy of Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Multi-Center Controlled Screening Trial of Safety and Efficacy of Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  12/31/1969
University of Tennessee
mi
from
Memphis, TN
Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Multi-Center Controlled Screening Trial of Safety and Efficacy of Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 12/31/1969
University of Tennessee
mi
from
Memphis, TN
Click here to add this to my saved trials
Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Multi-Center Controlled Screening Trial of Safety and Efficacy of Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  12/31/1969
Methodist Hospital System
mi
from
Houston, TX
Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Multi-Center Controlled Screening Trial of Safety and Efficacy of Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 12/31/1969
Methodist Hospital System
mi
from
Houston, TX
Click here to add this to my saved trials
Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Multi-Center Controlled Screening Trial of Safety and Efficacy of Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  12/31/1969
McGill University
mi
from
Montreal,
Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Multi-Center Controlled Screening Trial of Safety and Efficacy of Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 12/31/1969
McGill University
mi
from
Montreal,
Click here to add this to my saved trials
Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS
A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate Safety and Efficacy of Transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (MSC-NTF) in Patients With ALS
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS
A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate Safety and Efficacy of Transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (MSC-NTF) in Patients With ALS
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS
A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate Safety and Efficacy of Transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (MSC-NTF) in Patients With ALS
Status: Enrolling
Updated:  12/31/1969
UMass Medical School
mi
from
Worcester, MA
Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS
A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate Safety and Efficacy of Transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (MSC-NTF) in Patients With ALS
Status: Enrolling
Updated: 12/31/1969
UMass Medical School
mi
from
Worcester, MA
Click here to add this to my saved trials
Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS
A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate Safety and Efficacy of Transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (MSC-NTF) in Patients With ALS
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS
A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate Safety and Efficacy of Transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (MSC-NTF) in Patients With ALS
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Analysis of Post-Translational Modifications of a Critical Protein Implicated in Amyotrophic Lateral Sclerosis
Analysis of Post-Translational Modifications of a Critical Protein Implicated in Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  12/31/1969
UNC Neurology ALS clinic
mi
from
Chapel Hill, NC
Analysis of Post-Translational Modifications of a Critical Protein Implicated in Amyotrophic Lateral Sclerosis
Analysis of Post-Translational Modifications of a Critical Protein Implicated in Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 12/31/1969
UNC Neurology ALS clinic
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis
F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis (IND 123119 Protocol B)
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis
F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis (IND 123119 Protocol B)
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Brain and Nerve Stimulation for Hand Muscles in Spinal Cord Injury and ALS
Paired Stimulation to Increase Cortical Transmission to Hand Muscles: Pilot Study
Status: Enrolling
Updated:  12/31/1969
James J. Peters VA Medical Center, Bronx, NY
mi
from
Bronx, NY
Brain and Nerve Stimulation for Hand Muscles in Spinal Cord Injury and ALS
Paired Stimulation to Increase Cortical Transmission to Hand Muscles: Pilot Study
Status: Enrolling
Updated: 12/31/1969
James J. Peters VA Medical Center, Bronx, NY
mi
from
Bronx, NY
Click here to add this to my saved trials
A Trial of Tocilizumab in ALS Subjects
A Phase 2 Randomized, Placebo Controlled Trial of Tocilizumab in ALS Subjects
Status: Enrolling
Updated:  12/31/1969
Barrow Neurological Institute
mi
from
Phoenix, AZ
A Trial of Tocilizumab in ALS Subjects
A Phase 2 Randomized, Placebo Controlled Trial of Tocilizumab in ALS Subjects
Status: Enrolling
Updated: 12/31/1969
Barrow Neurological Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Trial of Tocilizumab in ALS Subjects
A Phase 2 Randomized, Placebo Controlled Trial of Tocilizumab in ALS Subjects
Status: Enrolling
Updated:  12/31/1969
University of Kansas Medical Center
mi
from
Kansas City, KA
A Trial of Tocilizumab in ALS Subjects
A Phase 2 Randomized, Placebo Controlled Trial of Tocilizumab in ALS Subjects
Status: Enrolling
Updated: 12/31/1969
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
A Trial of Tocilizumab in ALS Subjects
A Phase 2 Randomized, Placebo Controlled Trial of Tocilizumab in ALS Subjects
Status: Enrolling
Updated:  12/31/1969
Wake Forest University School of Medicine
mi
from
Winston-Salem, NC
A Trial of Tocilizumab in ALS Subjects
A Phase 2 Randomized, Placebo Controlled Trial of Tocilizumab in ALS Subjects
Status: Enrolling
Updated: 12/31/1969
Wake Forest University School of Medicine
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Trial of Tocilizumab in ALS Subjects
A Phase 2 Randomized, Placebo Controlled Trial of Tocilizumab in ALS Subjects
Status: Enrolling
Updated:  12/31/1969
Penn State College of Medicine, Milton S. Hershey Medical Center
mi
from
Hershey, PA
A Trial of Tocilizumab in ALS Subjects
A Phase 2 Randomized, Placebo Controlled Trial of Tocilizumab in ALS Subjects
Status: Enrolling
Updated: 12/31/1969
Penn State College of Medicine, Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
A Trial of Tocilizumab in ALS Subjects
A Phase 2 Randomized, Placebo Controlled Trial of Tocilizumab in ALS Subjects
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
A Trial of Tocilizumab in ALS Subjects
A Phase 2 Randomized, Placebo Controlled Trial of Tocilizumab in ALS Subjects
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Methodology Study of Novel Outcome Measures to Assess Progression of ALS
Methodology Study of Novel Electrophysiological, Physical, and Imaging Outcome Measures to Assess the Progression of Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  12/31/1969
California Pacific Medical Center
mi
from
San Francisco, CA
Methodology Study of Novel Outcome Measures to Assess Progression of ALS
Methodology Study of Novel Electrophysiological, Physical, and Imaging Outcome Measures to Assess the Progression of Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 12/31/1969
California Pacific Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Methodology Study of Novel Outcome Measures to Assess Progression of ALS
Methodology Study of Novel Electrophysiological, Physical, and Imaging Outcome Measures to Assess the Progression of Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  12/31/1969
University of South Florida
mi
from
Tampa, FL
Methodology Study of Novel Outcome Measures to Assess Progression of ALS
Methodology Study of Novel Electrophysiological, Physical, and Imaging Outcome Measures to Assess the Progression of Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 12/31/1969
University of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
Methodology Study of Novel Outcome Measures to Assess Progression of ALS
Methodology Study of Novel Electrophysiological, Physical, and Imaging Outcome Measures to Assess the Progression of Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  12/31/1969
The Emory Clinic
mi
from
Atlanta, GA
Methodology Study of Novel Outcome Measures to Assess Progression of ALS
Methodology Study of Novel Electrophysiological, Physical, and Imaging Outcome Measures to Assess the Progression of Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 12/31/1969
The Emory Clinic
mi
from
Atlanta, GA
Click here to add this to my saved trials
Methodology Study of Novel Outcome Measures to Assess Progression of ALS
Methodology Study of Novel Electrophysiological, Physical, and Imaging Outcome Measures to Assess the Progression of Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Hospital
mi
from
Baltimore, MD
Methodology Study of Novel Outcome Measures to Assess Progression of ALS
Methodology Study of Novel Electrophysiological, Physical, and Imaging Outcome Measures to Assess the Progression of Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Methodology Study of Novel Outcome Measures to Assess Progression of ALS
Methodology Study of Novel Electrophysiological, Physical, and Imaging Outcome Measures to Assess the Progression of Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital, MA
mi
from
Charlestown, MA
Methodology Study of Novel Outcome Measures to Assess Progression of ALS
Methodology Study of Novel Electrophysiological, Physical, and Imaging Outcome Measures to Assess the Progression of Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital, MA
mi
from
Charlestown, MA
Click here to add this to my saved trials
Methodology Study of Novel Outcome Measures to Assess Progression of ALS
Methodology Study of Novel Electrophysiological, Physical, and Imaging Outcome Measures to Assess the Progression of Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Methodology Study of Novel Outcome Measures to Assess Progression of ALS
Methodology Study of Novel Electrophysiological, Physical, and Imaging Outcome Measures to Assess the Progression of Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Methodology Study of Novel Outcome Measures to Assess Progression of ALS
Methodology Study of Novel Electrophysiological, Physical, and Imaging Outcome Measures to Assess the Progression of Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  12/31/1969
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Methodology Study of Novel Outcome Measures to Assess Progression of ALS
Methodology Study of Novel Electrophysiological, Physical, and Imaging Outcome Measures to Assess the Progression of Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 12/31/1969
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Methodology Study of Novel Outcome Measures to Assess Progression of ALS
Methodology Study of Novel Electrophysiological, Physical, and Imaging Outcome Measures to Assess the Progression of Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  12/31/1969
UZ Leuven
mi
from
Leuven,
Methodology Study of Novel Outcome Measures to Assess Progression of ALS
Methodology Study of Novel Electrophysiological, Physical, and Imaging Outcome Measures to Assess the Progression of Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 12/31/1969
UZ Leuven
mi
from
Leuven,
Click here to add this to my saved trials
Methodology Study of Novel Outcome Measures to Assess Progression of ALS
Methodology Study of Novel Electrophysiological, Physical, and Imaging Outcome Measures to Assess the Progression of Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  12/31/1969
University of California San Diego Medical Center
mi
from
San Diego, CA
Methodology Study of Novel Outcome Measures to Assess Progression of ALS
Methodology Study of Novel Electrophysiological, Physical, and Imaging Outcome Measures to Assess the Progression of Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 12/31/1969
University of California San Diego Medical Center
mi
from
San Diego, CA
Click here to add this to my saved trials
Exposure to Neurotoxins as Risk Factors for ALS
Exposure to Neurotoxins as Risk Factors for ALS: Measurement of Genes, Proteins, Neurotoxicants, and Other Factors Potentially Associated With ALS
Status: Enrolling
Updated:  12/31/1969
New England Medical Center
mi
from
Boston, MA
Exposure to Neurotoxins as Risk Factors for ALS
Exposure to Neurotoxins as Risk Factors for ALS: Measurement of Genes, Proteins, Neurotoxicants, and Other Factors Potentially Associated With ALS
Status: Enrolling
Updated: 12/31/1969
New England Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
Carol & Frank Morsani Center for Advanced Health Care - University of South Florida
mi
from
Tampa, FL
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
Carol & Frank Morsani Center for Advanced Health Care - University of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
Hospital for Special Surgery
mi
from
New York, NY
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
Hospital for Special Surgery
mi
from
New York, NY
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
Duke Neurological Disorders Clinic
mi
from
Durham, NC
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
Duke Neurological Disorders Clinic
mi
from
Durham, NC
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
Texas Neurology, PA
mi
from
Dallas, TX
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
Texas Neurology, PA
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
Neurosciences Institute: Neurology - Charlotte
mi
from
Charlotte, NC
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
Neurosciences Institute: Neurology - Charlotte
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
Providence Brain and Spine Inst. ALS Center
mi
from
Portland, OR
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
Providence Brain and Spine Inst. ALS Center
mi
from
Portland, OR
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
Temple University School of Medicine
mi
from
Philadelphia, PA
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
Temple University School of Medicine
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
St. Joseph's Hospital and Medical Center - Barrow Neurology Clinics
mi
from
Phoenix, AZ
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
St. Joseph's Hospital and Medical Center - Barrow Neurology Clinics
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
UC Davis Medical Center
mi
from
Sacramento, CA
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
UC Davis Medical Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
Forbes Norris MDA/ALS Research Center
mi
from
San Francisco, CA
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
Forbes Norris MDA/ALS Research Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
Hospital for Special Care
mi
from
New Britain, CT
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
Hospital for Special Care
mi
from
New Britain, CT
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic
mi
from
Jacksonville, FL
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
University of Miami Miller School of Medicine
mi
from
Miami, FL
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
University of Miami Miller School of Medicine
mi
from
Miami, FL
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
Indiana University
mi
from
Indianapolis, IN
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
University of Massachusetts Memorial Medical Center/University of Massachusetts Medical School
mi
from
Worcester, MA
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
University of Massachusetts Memorial Medical Center/University of Massachusetts Medical School
mi
from
Worcester, MA
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
Henry Ford Health System
mi
from
Detroit, MI
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated:  12/31/1969
Neurological Institute
mi
from
New York, NY
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status: Enrolling
Updated: 12/31/1969
Neurological Institute
mi
from
New York, NY
Click here to add this to my saved trials